scholarly journals P32 Bone inflammation and fever: an atypical presentation of chronic recurrent multifocal osteomyelitis (CRMO)?

Rheumatology ◽  
2018 ◽  
Vol 57 (suppl_8) ◽  
Author(s):  
Kathy Gallagher ◽  
Kate Armon ◽  
Peter Bale
2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Hon Yan Ng ◽  
Orlee R. Guttman ◽  
Lori B. Tucker

Abstract Background Chronic Recurrent Multifocal Osteomyelitis (CRMO) is a condition characterized by sterile bone inflammation, usually occurring in childhood. Although the etiology remains unclear, this condition has been associated with inflammatory bowel disease (IBD). Primary sclerosing cholangitis (PSC) and Autoimmune Hepatitis (AIH) are also uncommon pediatric conditions with a known association with IBD. Case presentation We present a unique case of a pediatric patient with an initial diagnosis of CRMO, with subsequent diagnosis of autoimmune hepatitis and PSC overlap, and eventually IBD. Conclusions Patients with CRMO may also develop PSC in addition to IBD, further highlighting the importance of IBD pathophysiology in both conditions. Clinical screening of associated gastrointestinal findings may be of value in patients with CRMO.


2015 ◽  
Vol 44 (9) ◽  
pp. 1359-1364 ◽  
Author(s):  
Cheng William Hong ◽  
Edward C. Hsiao ◽  
Andrew E. Horvai ◽  
Thomas M. Link

2016 ◽  
Vol 43 (11) ◽  
pp. 1956-1964 ◽  
Author(s):  
Sigrun R. Hofmann ◽  
Anja Schnabel ◽  
Angela Rösen-Wolff ◽  
Henner Morbach ◽  
Hermann J. Girschick ◽  
...  

Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disorder, covering a clinical spectrum with asymptomatic inflammation of single bones at the one end, and chronic recurrent multifocal osteomyelitis (CRMO) at the other end. The exact molecular pathophysiology of CNO remains largely unknown. Provided familial clusters and the association with inflammatory disorders of the skin and intestine suggest a genetic predisposition. Recently, profound dysregulation of cytokine responses was demonstrated in CRMO. Failure to produce antiinflammatory cytokines interleukin (IL)-10 and IL-19 contributes to activation of inflammasomes and subsequent IL-1β release. In IL-10–deficient and in CNO-prone chronic multifocal osteomyelitis mice, IL-1β was linked to bone inflammation. Further, alterations to the gut microbiome were suggested in contributing to IL-1β release from innate immune cells in mice, offering an interesting target in the search for molecular mechanisms in CNO. Here, we summarize clinical presentation and treatment options in CNO/CRMO, current pathophysiological concepts, available mouse models, and promising future scientific directions.


2021 ◽  
Vol 49 (9) ◽  
pp. 030006052110429
Author(s):  
Min Cheol Kim ◽  
Kyeong Ok Kim ◽  
Min Kyu Kang ◽  
Byung Ik Jang

Chronic recurrent multifocal osteomyelitis (CRMO) is a rare condition characterized by chronic relapsing noninfectious bone inflammation of unknown etiology. Although CRMO is considered an extraintestinal manifestation in patients with inflammatory bowel disease, most cases of CRMO are associated with Crohn’s disease; very few are associated with ulcerative colitis (UC). We herein describe a 21-year-old patient with UC who developed recurrent left thigh pain. The patient was diagnosed with CRMO associated with UC, which was well controlled with azathioprine treatment.


Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 4005
Author(s):  
Erika Cantarelli ◽  
Francesco Baccelli ◽  
Gabriele Simonini ◽  
Patrizia Alvisi

The efficacy of diet and its influence on gut microbiome composition has been largely demonstrated in inflammatory bowel disease (IBD). Little is known about its potential in the management of extraintestinal manifestations. We report a successful application of Crohn disease exclusion diet (CDED) in association with infliximab and methotrexate, as salvage therapy in a child affected by chronic recurrent multifocal osteomyelitis (CRMO) and Crohn disease (CD) resistant to optimized therapy. Both intestinal and bone symptoms remitted after the application of CDED. Diet may have acted on common microbic inciting agents that trigger both intestinal and bone inflammation, supporting the role of microbiota in the pathogenesis of IBD-associated extraintestinal manifestations. Our experience suggests the potential benefit of CDED in association with combined therapy in resistant patients affected by CD and extraintestinal manifestations.


2015 ◽  
Author(s):  
Dionysios Alexandrou ◽  
Benjamin Jacobs ◽  
O'Donnell Paul ◽  
Rikin Hargunani ◽  
Ananya Guha ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document